EUVIMEDEUVIMED entdecken
Crossref

3056-LB: Human Metabolomics Identifies Metabolite Candidates That Attenuate Skeletal Muscle Atrophy

SU-YEON PARK, BONGGI LEE

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-3056-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SU-YEON PARK und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Sarcopenia contributes to metabolic dysfunction and physical decline during aging. However, metabolites regulating muscle atrophy remain poorly defined. We aimed to identify metabolite candidates associated with sarcopenia progression and evaluate their effects in muscle atrophy models.

Methods

Public skeletal muscle metabolomics datasets across sarcopenia progression were analyzed to identify metabolites showing consistent changes. Candidate metabolites were prioritized using computational annotation. Selected metabolites were tested in differentiated C2C12 myotubes exposed to dexamethasone- or statin-induced atrophic stress, and myotube diameter was quantified.

Results

Metabolomics-guided prioritization identified metabolite candidates that progressively declined across stages of sarcopenia. Functional screening in C2C12 myotubes showed that several candidates partially restored myotube diameter under glucocorticoid- or statin-induced atrophic conditions (Fig.1). Additional in vitro and in vivo studies are currently underway to further evaluate candidate metabolites and their mechanisms of action.

Conclusion

These findings identify metabolite candidates associated with sarcopenia progression and suggest that metabolic modulation may attenuate skeletal muscle atrophy and support muscle metabolic resilience. Disclosure S. Park: None. B. Lee: None. Funding National Research Foundation of Korea (RS-2021-NR060118), National Research Foundation of Korea (RS-2023-00274576), Ministry of Oceans and Fisheries (RS-2025-02373103)

Zitieren

APA

PARK, S., & LEE, B. (2026). 3056-LB: Human Metabolomics Identifies Metabolite Candidates That Attenuate Skeletal Muscle Atrophy. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3056-lb

Vancouver

PARK S, LEE B. 3056-LB: Human Metabolomics Identifies Metabolite Candidates That Attenuate Skeletal Muscle Atrophy. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3056-lb

BibTeX
@article{PARK2026,
  author = {PARK, SU-YEON and LEE, BONGGI},
  title = {3056-LB: Human Metabolomics Identifies Metabolite Candidates That Attenuate Skeletal Muscle Atrophy},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-3056-lb}
}
Kostenlos starten →